Amplyx Pharmaceuticals Inc., which just raised $67m in Series C venture capital, is developing an antifungal drug that hits on a lot of key metrics for biopharmaceutical investors while potentially meeting the need for new agents to treat very sick patients who happen to contract life-threatening infections.
For Amplyx's backers, like Series C lead investor Sofinnova Venture Partners, the San Diego, Calif.-based company's novel drug candidate APX001 is eligible for expedited regulatory approvals, will enter into a market with few other treatment options, and could reduce costs elsewhere in the health care system
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?